Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Update

Acasti Pharma Inc. (NASDAQ:ACST) was the recipient of a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 5,900 shares, a growth of 34.1% from the May 31st total of 4,400 shares. Based on an average daily volume of 18,200 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.1% of the shares of the company are short sold.

Acasti Pharma Stock Up 0.7 %

Shares of NASDAQ:ACST opened at $2.99 on Friday. The firm has a market capitalization of $28.11 million, a PE ratio of -2.08 and a beta of 1.61. Acasti Pharma has a twelve month low of $1.72 and a twelve month high of $3.84. The company has a 50-day moving average price of $2.93 and a two-hundred day moving average price of $2.93.

Acasti Pharma (NASDAQ:ACST) last issued its earnings results on Friday, June 21st. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.30. Analysts anticipate that Acasti Pharma will post -1.29 earnings per share for the current fiscal year.

About Acasti Pharma

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.